Calithera Biosciences Reports Phase I Data for CB-839 in Patients With Hematological Malignancies at #ASH2015

Calithera Biosciences, Inc.

announced that clinical and preclinical data from its lead product candidate CB-839, a first-in-class glutaminase inhibitor was presented today at the 57th American Society of Hematology Annual Meeting (ASH), in Orlando, Florida.  The data demonstrated the clinical activity, tolerability and unique mechanism of action of CB-839 in patients with acute myeloid leukemia (AML) and multiple myeloma. "We are encouraged by the promising clinical activity of CB-839 as a single agent in AML, and early tolerability and preliminary signals of efficacy in combination therapy in multiple myeloma," said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera.  "We are actively enrolling six combination expansion cohorts of CB-839 in solid and hematological malignancies and look forward to presenting additional combination data in 2016." CB-839 in Multiple Myeloma Dr. Dan Vogl from the University of Pennsylvania presented a poster titled, "Phase I study of CB-839,